Back to Search Start Over

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 MAB) in relapsed/refractory multiple myeloma (RRMM)

Authors :
Vij, R Martin, T Richter, J Cole, C Atanackovic, D Zonder, J Kaufman, J Mikhael, J Bensinger, W Dimopoulos, M others
Publication Year :
2016

Subjects

Subjects :
Health Sciences
Επιστήμες Υγείας

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.dedup.wf.001..1ab7220178c83d1b13613b4fe189411e

Tools

Authors Abstract Subjects Details